Comparison of the effect of Cabergoline versus Dienogest on markers in endometriosis
Not Applicable
Not yet recruiting
- Conditions
- Health Condition 1: N801- Endometriosis of ovary
- Registration Number
- CTRI/2023/04/051886
- Lead Sponsor
- il
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Women with diagnosis of endometriosis on laparoscopy or ultrasound.
Exclusion Criteria
1.Women who want to conceive immediately.
2.Body mass index of (BMI) more than 30 kg/m2
3.Chronic inflammatory disorders
4.History of recent infection and inflammatory conditions (3months)
5.Patients with known history of allergy to one of the study drug
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in the serum levels of pro inflammatory levels post treatment <br/ ><br>1.Serum Vascular endothelial growth factor level <br/ ><br>2.Serum Tumor necrosis factor alpha level <br/ ><br>3.Serum high sensitivity C Reactive protein <br/ ><br>Timepoint: 0,6,9 months
- Secondary Outcome Measures
Name Time Method To compare the efficacy of cabergoline with dienogest on <br/ ><br>1.Reduction in post treatment pain by VAS <br/ ><br>2.Reduction in post treatment volume measured on USG <br/ ><br>3.Pain scoring by VAS after 3 months of stopping drug <br/ ><br>Timepoint: 0,3,6,9 months